Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420316
Status:
COMPLETED
Last Update Posted:
2018-08-28
First Post:
2007-01-10
Brief Title:
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bios HRV Vaccine
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
To Assess Long-term Efficacy Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline GSK Biologicals Oral Live Attenuated Human Rotavirus HRV Vaccine Rotarix in the Primary Vaccination Study 102247
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals oral live attenuated HRV vaccine Rotarix in the primary vaccination study 102247 The Rotarix vaccine was administered in the primary vaccination study There was no vaccineintervention in this long-term efficacy study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None